Literature DB >> 18227223

Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).

Thomas Schröter1, Dmitriy Minond, Amiee Weiser, Chinh Dao, Jeff Habel, Timothy Spicer, Peter Chase, Pierre Baillargeon, Louis Scampavia, Stephan Schürer, Caty Chung, Chris Mader, Mark Southern, Nick Tsinoremas, Philip LoGrasso, Peter Hodder.   

Abstract

Kinases are important drug discovery targets for a wide variety of therapeutic indications; consequently, the measurement of kinase activity remains a common high-throughput screening (HTS) application. Recently, enzyme-coupled luciferase-kinase (LK) format assays have been introduced. This format measures luminescence resulting from metabolism of adenosine triphosphate (ATP) via a luciferin/luciferase-coupled reaction. In the research presented here, 1536-well format time-resolved fluorescence resonance energy transfer (TR-FRET) and LK assays were created to identify novel Rho-associated kinase II (ROCK-II) inhibitors. HTS campaigns for both assays were conducted in this miniaturized format. It was found that both assays were able to consistently reproduce the expected pharmacology of inhibitors known to be specific to ROCK-II (fasudil IC50: 283 +/- 27 nM and 336 +/- 54 nM for TR-FRET and LK assays, respectively; Y-27632 IC50: 133 +/- 7.8 nM and 150 +/- 22 nM for TR-FRET and LK assays, respectively). In addition, both assays proved robust for HTS efforts, demonstrating excellent plate Z' values during the HTS campaign (0.84 +/- 0.03; 0.72 +/- 0.05 for LK and TR-FRET campaigns, respectively). Both formats identified scaffolds of known and novel ROCK-II inhibitors with similar sensitivity. A comparison of the performance of these 2 assay formats in an HTS campaign was enabled by the existence of a subset of 25,000 compounds found in both our institutional and the Molecular Library Screening Center Network screening files. Analysis of the HTS campaign results based on this subset of common compounds showed that both formats had comparable total hit rates, hit distributions, amount of hit clusters, and format-specific artifact. It can be concluded that both assay formats are suitable for the discovery of ROCK-II inhibitors, and the choice of assay format depends on reagents and/or screening technology available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227223     DOI: 10.1177/1087057107310806

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  11 in total

1.  A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.

Authors:  Douglas S Auld; Ya-Qin Zhang; Noel T Southall; Ganesha Rai; Marc Landsman; Jennifer MacLure; Daniel Langevin; Craig J Thomas; Christopher P Austin; James Inglese
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

2.  Comparison of bioluminescent kinase assays using substrate depletion and product formation.

Authors:  Cordelle Tanega; Min Shen; Bryan T Mott; Craig J Thomas; Ryan MacArthur; James Inglese; Douglas S Auld
Journal:  Assay Drug Dev Technol       Date:  2009-12       Impact factor: 1.738

3.  Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase.

Authors:  Toshimitsu Takagi; David Shum; Monika Parisi; Ruth E Santos; Constantin Radu; Paul Calder; Zahra Rizvi; Mark G Frattini; Hakim Djaballah
Journal:  Comb Chem High Throughput Screen       Date:  2011-09       Impact factor: 1.339

4.  Discovery of Potent and Selective Urea-Based ROCK Inhibitors and Their Effects on Intraocular Pressure in Rats.

Authors:  Yan Yin; Michael D Cameron; Li Lin; Susan Khan; Thomas Schröter; Wayne Grant; Jennifer Pocas; Yen Ting Chen; Stephan Schürer; Alok Pachori; Philip LoGrasso; Yangbo Feng
Journal:  ACS Med Chem Lett       Date:  2010-04-05       Impact factor: 4.345

Review 5.  Discovery of novel inhibitors for the treatment of glaucoma.

Authors:  Kishore Cholkar; Hoang M Trinh; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Discov       Date:  2015-01-09       Impact factor: 6.098

6.  HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.

Authors:  François Degorce; Amy Card; Sharon Soh; Eric Trinquet; Glenn P Knapik; Bing Xie
Journal:  Curr Chem Genomics       Date:  2009-05-28

7.  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.

Authors:  Yangbo Feng; Yan Yin; Amiee Weiser; Evelyn Griffin; Michael D Cameron; Li Lin; Claudia Ruiz; Stephan C Schürer; Toshihiro Inoue; P Vasanth Rao; Thomas Schröter; Philip Lograsso
Journal:  J Med Chem       Date:  2008-10-04       Impact factor: 7.446

8.  Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

Authors:  Dmitriy Minond; S Adrian Saldanha; Prem Subramaniam; Michael Spaargaren; Timothy Spicer; Joseph R Fotsing; Timo Weide; Valery V Fokin; K Barry Sharpless; Moreno Galleni; Carine Bebrone; Patricia Lassaux; Peter Hodder
Journal:  Bioorg Med Chem       Date:  2009-06-22       Impact factor: 3.641

9.  Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease.

Authors:  Haifeng Geng; Grace Whiteley; Jameson Ribbens; Wei Zheng; Noel Southall; Xin Hu; Juan J Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

Review 10.  Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.

Authors:  Rand Shahin; Omar Shaheen; Faris El-Dahiyat; Maha Habash; Sana Saffour
Journal:  Future Sci OA       Date:  2017-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.